



Contents lists available at ScienceDirect

## Journal of Pharmaceutical Sciences

journal homepage: [www.jpharmsci.org](http://www.jpharmsci.org)

Pharmaceutics, Drug Delivery and Pharmaceutical Technology

## A Tutorial for Developing a Topical Cream Formulation Based on the Quality by Design Approach

Ana Simões<sup>1,2</sup>, Francisco Veiga<sup>1,2</sup>, Carla Vitorino<sup>1,2,3</sup>, Ana Figueiras<sup>1,2,\*</sup><sup>1</sup> Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal<sup>2</sup> LAQV. REQUIMTE, Group of Pharmaceutical Technology, Coimbra, Portugal<sup>3</sup> Center for Neurosciences and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal

## ARTICLE INFO

## Article history:

Received 9 April 2018

Revised 7 June 2018

Accepted 12 June 2018

Available online 20 June 2018

## Keywords:

quality by design

quality target product profile

critical quality attributes

critical material attributes

critical process parameters

## ABSTRACT

The pharmaceutical industry has entered in a new era, as there is a growing interest in increasing the quality standards of dosage forms, through the implementation of more structured development and manufacturing approaches. For many decades, the manufacturing of drug products was controlled by a regulatory framework to guarantee the quality of the final product through a fixed process and exhaustive testing. Limitations related to the Quality by Test system have been widely acknowledged. The emergence of Quality by Design (QbD) as a systematic and risk-based approach introduced a new quality concept based on a good understanding of how raw materials and process parameters influence the final quality profile. Although the QbD system has been recognized as a revolutionary approach to product development and manufacturing, its full implementation in the pharmaceutical field is still limited. This is particularly evident in the case of semisolid complex formulation development. The present review aims at establishing a practical QbD framework to describe all stages comprised in the pharmaceutical development of a conventional cream in a comprehensible manner.

© 2018 American Pharmacists Association<sup>®</sup>. Published by Elsevier Inc. All rights reserved.

## Introduction

Over the last decades, our understanding about physicochemical properties of topical formulations and their excipients, result in the ability to develop physical, chemical and biologically stable products. To design and develop a successful pharmaceutical dosage form for skin delivery, preformulation and formulation studies require particular considerations. Moreover, the knowledge of skin barrier structure and drug permeation properties is essential for a rational progress in the development of topical formulations.

Dosage forms for topical application are intended to produce the required therapeutic action at specific targets in the skin with the least probable adverse effects.<sup>1,2</sup> Topical formulations can be easily administered and transported, and are used for the treatment of several disorders. For any topical formulation, the onset, rate, and extent of therapeutic response depend on the efficiency of sequential processes: release of the active substance from the dosage form, penetration/diffusion of the drug through the *stratum corneum* (SC), and other skin layers, before producing the

pharmacological effect. These different processes are variables which result in formulation safety and efficacy differences.<sup>3</sup> There are several topical formulations available in the market; however, semisolids (e.g., ointments, creams and gels) are the most commonly used for this purpose.<sup>4</sup>

Included in the latter category, conventional creams/emulsions represent a promising pharmaceutical vehicle for skin drug delivery despite their thermodynamic instability and complex formulation remaining a challenge for pharmaceutical technology.<sup>5</sup> Depending on the physicochemical properties, desired site of action, and drug delivery strategies, drugs incorporated into semisolid products can be applied for different purposes. A cream is a semisolid emulsion containing one or more active substances, dissolved or dispersed, and may be defined as a biphasic system in which the dispersed or internal phase is finely and uniformly dispersed in the continuous or external phase. According to the dispersed phase nature, it is possible to acquire an oil-in-water cream (o/w) or a water-in-oil cream (w/o).<sup>4,6</sup>

Besides the several aspects taken into account in cream product design, during the whole process, it is imperative to preserve a high quality level. Thereby, in cream research and development, the application of a systematic approach is demanded to avoid product rejections during manufacturing and to achieve regulatory approval.

\* Correspondence to: Ana Figueiras (Telephone: +351-239-488-431).  
E-mail address: [rfigueiras@ff.uc.pt](mailto:rfigueiras@ff.uc.pt) (A. Figueiras).

Over the years, pharmaceutical industries have spent significant efforts to ensure product quality, to achieve regulatory compliance, and to yield pharmaceuticals as cost efficient as possible. Therefore, they perform sophisticated processes and technologies that require steadiness among scientific progress and operational complexity. Nonetheless, such processes do not present a rational understanding of critical variables and control strategies, which is imperative to ensure the product quality.<sup>7</sup>

In this context, the U.S. Food and Drug Administration has highlighted Quality by Design (QbD) as current Good Manufacturing Practices initiative for the 21st century. The emergence of this approach has added a new dimension to pharmaceutical development and manufacturing.<sup>8–10</sup>

The implementation of the QbD approach includes the definition of the quality target product profile (QTPP) and critical quality attributes (CQAs) of drug product, the accomplishment of risk assessment (International Conference on Harmonisation [ICH] Q9) to identify critical material attributes (CMAs) and critical process parameters (CPPs), the definition of a design space through design of experiments (DoEs), the establishment of a control strategy, and the continual improvement and innovation throughout the product life cycle.<sup>11</sup>

As mentioned in the Q8 guideline, the aim of the pharmaceutical development based on a QbD approach is to design a successful product and its manufacturing process according to the intended quality performance. During product development, a detailed identification, understanding, and control of critical variables, with their optimal operating range definition, will enable to yield a product with the required quality profile. The information and knowledge gained from pharmaceutical development studies and manufacturing experience provide an enhancement of scientific understanding. Greater product and process understanding is also crucial for more flexible regulatory approaches. The degree of regulatory flexibility relies on the level of scientific knowledge provided in the registration dossier.

Although the implementation of the QbD principles is one step forward for conventional solid form development, the case of conventional semisolid forms still remain largely unexplained. This review focuses on QbD approach for the development of semisolid dosage forms, particularly on cream formulations. Employing QbD principles to a complex formulation such as a cream, an effective product development, with an optimized formulation, and a continuous and robust manufacturing process, may be easily achieved. Therefore, QbD approach will provide an opportunity for pharmaceutical companies to improve formulation and manufacturing efficiencies and productivity, with significant reduction in cost production, product variability, defects, and batch rejection, so as to get more flexible regulatory approvals, to decrease postapproval changes and to produce high-quality pharmaceuticals under real-time release.<sup>11–15</sup> Thus, the predicted level established through this system is expected to be a scientific and technological progress for industries and regulatory authorities.

### QbD Approach—Cream Development Strategy

#### Definition of Conventional Cream QTPP and CQAs

The initial step when using QbD-based development is to predefine the final quality profile. QTPP comprises cream quality parameters that should be ideally achieved at the final stage of the product development and production, considering its safety and efficacy.

The second step of the QbD-based development is to identify the critical quality parameters. Derived from QTPP, CQAs are quality

cream development and manufacturing to guarantee predefined product quality.<sup>7,11,16–18</sup> An example of cream QTPP and its CQAs is provided in Table 1.

#### Product Design and Development

Once the dosage form is selected, the drug product development using the QbD approach is initiated. The main purpose of the product design is to develop a robust cream that can achieve the therapeutic objectives and quality attributes, remaining stable over the shelf life.

#### Drug Substance

The physicochemical and biological properties of the drug substance have a significant effect on drug product performance and manufacturability. Thereby, these properties must be identified to produce the right dosage form and to select the appropriate drug concentration, excipients, and process parameters.

During preformulation studies, drug properties such as solubility, partition coefficient ( $\log p$ ), particle size, pKa, permeability, melting point, and molecular weight need to be identified because of their role on percutaneous permeation.<sup>8,11,19,20</sup>

The quality attributes of drug substance will ensure that the drug product meets its CQAs and must be controlled within the defined specifications.<sup>21</sup>

#### Excipient Selection

Special consideration needs to be given to excipient selection because of their influence also on the final product performance, manufacturability, and stability. This selection is related to the intended dosage form, route of administration, safety profile, manufacturing process, and regulatory aspects. Excipient nature and concentration will determine drug release from the dosage form, skin barrier features and drug penetration/diffusion, affecting the duration and extent of the therapeutic action at the target skin layer.<sup>22</sup>

In cream formulation, excipients are used to improve drug solubility and to incorporate it at the target concentration (solvents), to control drug release and cream viscosity (thickeners), to improve drug skin permeability (chemical permeation enhancers), to enhance drug and formulation stability (antioxidants, emulsifiers and buffers), and to prevent microbial growth and contamination (preservatives).<sup>23</sup> Acceptable pharmaceutical excipients are listed in international pharmacopoeias for pharmaceutical product development.<sup>4</sup>

At this stage, special consideration must be given to drug solubility because it will dictate the excipient selection because of its impact on diffusion through each skin environment, as well as on release pattern from the dosage form vehicle, final cream uniformity, and stability. If a suitable solvent is selected, to comprise the solubilizing phase of the emulsion system, an excellent skin permeation rate of the drug substance will be provided. According to drug physicochemical properties and dosage form (aqueous or oily solubilizing phase nature), different solvents have to be wisely selected and tested. The equilibrium solubility is defined as the maximum quantity of a drug which can be completely dissolved, at a given temperature and pressure, in a specific amount of solvent. Therefore, for a specific drug substance in the solid form, it is imperative to perform a solvent screening to determine the active equilibrium solubility in each promising solvent and later in the solvent blend/solubilizing phase.<sup>24–26</sup>

Another important parameter to be considered for drug release performance and percutaneous absorption rate assessment is the thermodynamic activity of the drug in the formula-

**Table 1**  
Example of General Elements of QTPP and CQAs for a Conventional Cream Formulation

| QTPP                            | Target  | CQAs | Justification  |
|---------------------------------|---|------|--|
| Dosage form                     | Cream   | –    | –  |
| Route of administration         | Topical   | –    | Local administration avoiding systemic side effects  |
| Dosage strength                 | % w/w   | –    | –  |
| Dosage design                   | Oil in water emulsion cream with API dispersed in the cream base  | –    | –  |
| Appearance                      | White smooth cream with dispersed API                             | –    | –  |
| Identification                  | USP <621>/Eur. Ph. 2.2.29   | –    | –  |
| Assay                           | 80%-90% of the saturation concentration in the solubilizing phase | Yes  | To set up the dose that will ensure drug availability to promote therapeutic effect                                    |
| Impurities                      | USP <1086>/Eur. Ph. 5.20  | Yes  | Should be maintained below set limits to ensure safety and efficacy of formulation                                     |
| Uniformity                      | USP <905>/Eur. Ph. 2.9.40   | Yes  | To assure consistency of the delivery system performance   |
| API particle size               | USP <429>/Eur. Ph. 2.9.31   | Yes  | Smaller size facilitates drug permeation   |
| API crystallization             | USP <854>/Eur. Ph. 2.2.24   | –    | Impact on formulation uniformity and stability   |
| pH                              | USP <791>/Eur. Ph. 2.2.3  | Yes  | Impact on physicochemical stability  |
| Viscosity                       | USP <911>/Eur. Ph. 2.2.9  | Yes  | To increase drug residence time at the site of application and consequently its action duration/To ensure drug release |
| Oil droplet size                | USP <776>/Eur. Ph. 2.9.37   | Yes  | Impact on release/permeation behavior  |
| <i>In vitro</i> release profile | <i>In vitro</i> Release Testing Guidance                          | Yes  | To assess formulation delivery performance for enhanced therapeutic efficacy   |
| Preservatives content           | Consult USP <51>/Eur. Ph. 5.1.3                                   | –    | –  |
| Microbial limits                | USP <61>/Eur. Ph. 2.6.12  | Yes  | Must be maintained below the specified limits to ensure formulation safety and stability                               |
| Residual solvents               | USP <467>/Eur. Ph. 5.4  | –    | –  |
| Stability                       | ICH Q1 A  | Yes  | Quality requirement  |
| Container closure system        | Appropriate for the dosage form                                   | –    | To ensure target shelf-life  |
| Package integrity               | Compatible  | –    | –  |

API, active pharmaceutical ingredient; EE, encapsulation efficiency; Eur. Ph., European Pharmacopeia; PDI, polydispersity index; USP, United States Pharmacopeia.

solution is yielded and a higher thermodynamic activity is achieved, increasing the driving force drug diffusion from the formulation.<sup>27-32</sup>

Compatibility among excipients and drug(s) must be evaluated to anticipate any stability failures and possible incompatibilities in the final formulation.<sup>19</sup> These studies are imperative in the drug product development process because the acquired information from compatibility data is applied to select the suitable excipients, to ensure active substance stability, to understand degradation products and its formation pathway, and to investigate reaction mechanisms, which help to prevent unexpected hurdles and identify stable storage conditions.<sup>33</sup>

In the pharmaceutical technological field, there are different accepted methods for drug and excipients compatibility analysis. The accelerated stability test is the most common to evaluate chemical compatibility for topical formulation development.<sup>34</sup>

In the sections that follow, the choice of excipients, their concentration, and characteristics that can influence the drug product performance are discussed as well as their corresponding functions.

#### Choice of the Oily Phase

External emulsions comprise oily compounds as active substance carriers. There are different oily excipients suitable to use in cream formulations. Saturated and unsaturated fatty acids/fatty acid esters,<sup>35</sup> hydrocarbons, and polyols can constitute the oily phase, also functioning as penetration enhancers, and consistency or viscosity modifiers. Therefore, the selected oily excipients may also influence cream viscosity, drug solubility, physical stability, drug release performance and transport into the skin. Controlling emulsion consistency will ensure cream spreadability, but it needs to be slimy enough to form a continuous film over the skin.<sup>36</sup>

#### Thickeners and Emulsifying Agents

The physicochemical principles underlying emulsion formula-

liquids are mechanically mixable without any interfacial stabilization, both liquids will form droplets, which rapidly flocculate (aggregation of dispersed droplets), coalesce (aggregation of flocculated droplets with possible oily and water phases separation), and form a creamy layer (dispersed phase droplets on the top of the continuous phase).<sup>37,38</sup> Physical stability is determined by the ability to mitigate these physical instability phenomena, and it may be accomplished by increasing the viscosity of the continuous phase, reducing the droplet movement rate of the dispersed phase, or decreasing interfacial tension between both phases by an emulsifier addition.

It has been described a direct relationship among cream viscosity and the viscosity of its continuous phase, but it is also possible to improve its apparent viscosity by increasing the concentration of the dispersed phase or reducing mean droplet size during homogenization process. A high apparent viscosity is imperative to retard the movement of dispersed phase droplets, keeping an emulsion physically stable.<sup>36</sup>

Thickeners are important excipients with impact on cream viscosity and, consequently, on skin retention of the topical dosage form and on drug penetration. Thereby, it is crucial to carry out *in vitro* skin permeation studies to assess formulation release behavior. For example, the inclusion of methylcellulose and paraffin reduces dispersed droplets mobility in an o/w emulsion and in a w/o emulsion, respectively.

Apparent viscosity can be also controlled by the homogenization process. This unit operation allows the reduction of droplet size and thus increases their number and surface area, increasing cream viscosity.

The inclusion of emulsifying agent(s) is also imperative to assist the emulsification process during cream manufacturing and to ensure emulsion physical stability during the product shelf life. When an emulsion formulation is developed, the type of emulsifying agent (anionic, cationic or nonionic), hydrophilic-lipophilic

to be considered in the emulsifier selection. Although this task seems to be limitless, there are some guidelines that may help in their correct choice. First of all, the use of pharmaceutically approved excipients will reduce regulatory justification periods. Emulsifier agent nature is extremely important for emulsion stabilization and generalization; ionic surfactants are used in o/w emulsions, whereas nonionic surfactants can be used in both o/w and w/o formulations. Essential information is provided by HLB system, a useful method for calculating the relative emulsifier amounts necessary to produce the most physically stable emulsion. Each surfactant is associated to an HLB number (usually between 0 and 20), representing the relative ratio of surfactant lipophilic and hydrophilic proportions. Emulsifiers with high HLB values (hydrophilic or polar properties) enable to develop o/w emulsions, whereas surfactants with low HLB values (lipophilic or nonpolar characteristics) allow to formulate w/o emulsions.<sup>36</sup>

Physical stability of semisolid formulations can be assessed through different analytical methodologies. Microscopic examination, centrifugation tests, and viscosity analysis are essential techniques performed for this purpose.<sup>36,39,40</sup>

#### Preservatives and Antioxidants

Oils and fats used in emulsion formulation are susceptible to oxidation by atmospheric oxygen or the action of microorganisms. The atmosphere oxidation results in degradation products which confer unpleasant cream characteristics. The resulting instability can be prevented by introduction of excipients with antioxidant properties. The selection of the antioxidant and its concentration can only be determined by testing its effectiveness on the final product, according to pharmacopoeial information. Their efficiency depends on its compatibility with other excipients and on its oil/water partition coefficient.

Oxidation from microbiological source influences the physicochemical properties of the emulsion, such as color and odor changes, hydrolysis of fats and oils, pH changes in the aqueous phase, and breaking of emulsion. Emulsions with aqueous continuous phase nature are more susceptible to microbial contamination. Therefore, it is required to include antimicrobial agents (preservatives) to prevent any microorganism growth. A preservative suitable for an emulsion must present wide spectrum of bactericidal activity, low log *p*, compatibility with other excipients, stability, and effectiveness over a wide range of pH and temperatures.

#### Buffer Agents

To provide chemical stability and to ensure physical compatibility, it is necessary to include buffer agents, but these electrolytes have to be carefully added to avoid undesirable effects on physical stability (e.g., rheological behavior).<sup>36,40</sup>

All components are related to the requirement that formulation must be capable of delivering the correct amount of drug to the therapeutic application site, be free from microbial contamination, and physically unchanged since the manufacturing day.

#### Process Design and Development

Since a formulation cannot become a product without a process, process and product design and development cannot be separated. Process design is an initial phase of the process development and should include all factors that need to be considered in cream production, such as equipment, material transfer, and manufacturing variables. Therefore, process selection depends on the product design and material properties. Once process design

conducted in accordance to the cream QTPP, product, and process knowledge.

To produce the intended quality product, a series of unit operations are accomplished throughout the cream manufacturing process. A unit operation involves physical or chemical changes while process parameters are referred to the input operating parameters (e.g., speed) or variables associated with a specific operation (e.g., temperature).

#### Manufacturing Process

In cream formulation production, the first mechanical process carried out is the mixture of both the aqueous and oily phases by adding the dispersed to the continuous phase or of the continuous to the dispersed phase. Sometimes, o/w emulsions are prepared through the phase inversion technique, in which the aqueous phase is slowly added to the oily phase. Initially, a w/o emulsion is formed, but as further aqueous phase is added, the emulsion inverts to form an o/w emulsion. It should be evaluated the effect of the order of addition and the rate of addition on the drug product quality attributes.

Prior to mixing, different excipients are dissolved in the phase in which they are soluble. The initial mixing temperature of both phases should be high enough to ensure intimate liquid mixing and avoid premature solidification of the oily phase by the colder water. Aqueous phase should be warmed to a temperature slightly higher than the oily phase.

Some active pharmaceutical ingredients can be dissolved at high temperature and recrystallized during the cooling stage. In this case, the active substance can be carried to the cooled down cream base via a powder eduction system or through a slurry addition and simultaneously mixed into the cream base, thus preventing the recrystallization problem. The stage to introduce the active substance into the semisolid mixture may be critical and should be identified.<sup>20,39</sup>

The next step in cream production is the homogenization stage. Agitators, mechanical mixers, rotor stators, homogenizers, or ultrasonic devices could be employed to ensure uniform excipient dispersion and droplet size reduction. To remove cream air pockets, a deaeration via vacuum with low-speed mixing may be turned on to the system. Homogenization time and vacuum pressure are significant process variables that can affect physical stability (e.g., coalescence of droplets, phase separation) and homogeneity. During cream process development and manufacturing, time, temperature, and mechanical energy are high-risk variables of the homogenization equipment that must be controlled to produce consistent quality.


Furthermore, as cooling rate can influence the final product quality, different cooling rates after melting, mixing, and homogenization steps should be additionally investigated as process variables.

Visual inspection is a useful and simple confirmatory test to ensure solid dissolution or uniformity system before proceeding to the next step. Microscopic visualizations should be also performed to select homogenization speed and time, so as to enable proper incorporation of the active substance into the base and conform the microscopic appearance, including drug particle size and droplet size.<sup>14,41</sup>

#### Risk Assessment

Based on prior knowledge, an initial risk assessment is performed to identify and prioritize potential high-risk variables that may influence identified cream CQAs. The outcome of this procedure is to determine which material attributes and process pa-





**Figure 1.** Ishikawa diagram showing critical parameters of a conventional cream pharmaceutical development. Log *p*, octanol-water partition coefficient.

investigated and controlled within appropriate ranges to ensure cream quality.

Using a risk approach, the starting point must be the identification of all material attributes and process parameters that can influence product CQAs and hence generate quality failure. To ascertain which of these parameters need to be further studied and controlled, an Ishikawa diagram is constructed (Fig. 1).<sup>42,43</sup> In addition, a risk estimation matrix (REM) is carried out to prioritize material attributes and process parameters that were demonstrated to be a potential risk factor for cream CQAs (Fig. 2).<sup>44-46</sup>

In pharmaceutical development, risk assessment analysis must be accomplished in early phases, but it is important to be updated at different development stages as further information becomes available and greater knowledge is obtained.<sup>47,48</sup> After risk assessment data analysis, specific parameters are, then, selected for subsequent screening studies (DoEs).

#### Identification of CMAs and CPPs

In cream development, several variables need to be considered and investigated to reach predefined QTPP. CMAs and CPPs that may specifically influence one or more cream CQAs must be identified to develop an adequate cream formulation (Tables 2 and 3).

Critical variable identification is the preliminary step in the optimization methodology, which is established through a screening process. A screening design is an experimental planning where a relatively large number of factors is simultaneously evaluated using a small number of experiments. During the screening phase, all factors are tested to indicate the most critical ones. These designs enable to detect which variables are responsible for the final product quality to eliminate all those ones which do not play an important role in ensuring quality constancy. Different experimental designs, such as, full factorial, fractional factorial, and Plackett-Burman, designs are usually used for

#### Formulation Optimization

After performing screening experiments, variables that show criticality in the previous phase are also optimized through a DoEs. The optimization stage aids to specify CMAs and CPPs optimal settings, and, ultimately, the definition of design space. Note that any manufacturing process developed within the design space will be regulatory acceptable.

Response surface designs, such as Central Composite Design and Box Behnken are the most usual models to predict the optimal CMAs and CPPs ranges. Currently, some software packages are available to simplify experimental design procedure and assist in results interpretation: MODDE, Design Expert Design-Ease, and JMP.<sup>52-56</sup> The application of the QbD concepts to optimize formulation, single-unit operation, or to the entire manufacturing process, is intended to support end-product quality and real-time release.<sup>11,14</sup>

#### Formulation Performance Testing

According to the predefined QTPP, cream performance needs to be assessed. There are 3 important CQAs to consider in topical formulation development: formulation stability, drug release profile, and skin permeation behavior.<sup>11,33,57</sup>

#### Stability Testing

To identify formulation stability issues, formulation stability studies must be performed.<sup>34</sup> This stage aims at developing a stability screen of prototype formulations to select the most promising ones for *in vitro* drug release and permeation testing.

#### In Vitro Release Studies

The release rate of an active substance from a dosage form is a critical feature for semisolid dermatological products because the

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.